Verona pharma reports first quarter 2025 financial results and provides corporate update

Total net revenue of $76.3 million from q1 2025 driven by ohtuvayre ® net sales of $71.3 million (+95% vs q4 2024)
VRNA Ratings Summary
VRNA Quant Ranking